AAPL344.66+5.16 (+1.52%) ▲|ABBV283.42-5.66 (-1.96%) ▼|ABT98.57-3.89 (-3.79%) ▼|ACN237.60-1.53 (-0.64%) ▼|ADBE255.28-1.45 (-0.56%) ▼|AMAT409.14+4.16 (+1.03%) ▲|AMD553.81+19.07 (+3.57%) ▲|AMGN437.33-1.61 (-0.37%) ▼|AMT178.95-4.61 (-2.51%) ▼|AMZN263.93+1.30 (+0.50%) ▲|AVGO338.58+4.21 (+1.26%) ▲|AXP323.66+5.32 (+1.67%) ▲|BA192.56+2.09 (+1.10%) ▲|BAC50.94+0.30 (+0.59%) ▲|BKNG158.82-5.10 (-3.11%) ▼|BLK1,142.09+13.41 (+1.19%) ▲|BMY60.82-0.87 (-1.40%) ▼|BNY146.54+2.29 (+1.59%) ▲|BRK-B542.08+2.26 (+0.42%) ▲|C123.61+1.10 (+0.90%) ▲|CAT741.55+16.31 (+2.25%) ▲|CL93.71-0.83 (-0.88%) ▼|CMCSA21.89-0.47 (-2.10%) ▼|COF208.30+6.74 (+3.34%) ▲|COP145.86-0.09 (-0.06%) ▼|COST996.30+1.69 (+0.17%) ▲|CRM242.29-0.14 (-0.06%) ▼|CSCO107.43+0.72 (+0.67%) ▲|CVS94.31-0.44 (-0.46%) ▼|CVX226.55+0.84 (+0.37%) ▲|DE632.65+0.45 (+0.07%) ▲|DHR230.57+6.33 (+2.82%) ▲|DIS111.38-0.29 (-0.26%) ▼|DUK121.06-0.28 (-0.23%) ▼|EMR164.95+4.49 (+2.80%) ▲|FDX299.55+0.79 (+0.26%) ▲|GD345.72+1.28 (+0.37%) ▲|GE298.48-1.39 (-0.46%) ▼|GEV928.88+38.55 (+4.33%) ▲|GILD153.46-3.05 (-1.95%) ▼|GM76.15-0.94 (-1.22%) ▼|GOOG330.45-5.95 (-1.77%) ▼|GOOGL334.59-5.69 (-1.67%) ▼|GS903.89+19.08 (+2.16%) ▲|HD314.43-0.68 (-0.22%) ▼|HON215.44+2.12 (+0.99%) ▲|IBM245.41+3.49 (+1.44%) ▲|INTC92.64+0.95 (+1.03%) ▲|INTU334.16-1.13 (-0.34%) ▼|ISRG429.84-8.16 (-1.86%) ▼|JNJ255.99-3.37 (-1.30%) ▼|JPM334.50-0.76 (-0.23%) ▼|KO92.67-0.82 (-0.88%) ▼|LIN502.06+0.17 (+0.03%) ▲|LLY1,270.37-13.29 (-1.04%) ▼|LMT548.75+0.04 (+0.01%) ▲|LOW196.54-0.75 (-0.38%) ▼|LRCX261.42-2.03 (-0.77%) ▼|MA623.34+2.92 (+0.47%) ▲|MCD245.86-0.66 (-0.27%) ▼|MDLZ62.47-1.53 (-2.38%) ▼|MDT93.52-1.11 (-1.17%) ▼|META707.79+13.54 (+1.95%) ▲|MMM174.01+2.64 (+1.54%) ▲|MO73.86-0.78 (-1.05%) ▼|MRK148.63+0.33 (+0.22%) ▲|MS184.97+4.57 (+2.53%) ▲|MSFT532.64+0.77 (+0.14%) ▲|MU917.85+21.78 (+2.43%) ▲|NEE78.69-0.18 (-0.22%) ▼|NFLX65.71-2.98 (-4.34%) ▼|NKE37.80-0.09 (-0.22%) ▼|NOW152.96+3.42 (+2.28%) ▲|NVDA221.37+4.90 (+2.26%) ▲|ORCL129.92-1.22 (-0.93%) ▼|PEP134.62+0.60 (+0.44%) ▲|PFE29.72-0.40 (-1.31%) ▼|PG157.73-1.59 (-1.00%) ▼|PLTR199.52+6.92 (+3.59%) ▲|PM196.84-3.07 (-1.53%) ▼|QCOM177.67+1.96 (+1.12%) ▲|RTX189.66-3.68 (-1.90%) ▼|SBUX98.74-0.64 (-0.64%) ▼|SCHW91.69+0.80 (+0.88%) ▲|SO90.53-0.18 (-0.20%) ▼|SPG206.14-0.85 (-0.41%) ▼|T21.96-1.46 (-6.23%) ▼|TMO694.24+6.87 (+1.00%) ▲|TMUS153.10-4.65 (-2.95%) ▼|TSLA386.45+12.74 (+3.41%) ▲|TXN288.23+10.45 (+3.76%) ▲|UBER68.23-0.72 (-1.04%) ▼|UNH417.32-1.94 (-0.46%) ▼|UNP289.18+1.57 (+0.55%) ▲|UPS100.18+1.66 (+1.68%) ▲|USB59.35+0.26 (+0.44%) ▲|V408.62+2.05 (+0.50%) ▲|VZ43.48-1.07 (-2.39%) ▼|WFC82.31+0.11 (+0.13%) ▲|WMT117.74-0.11 (-0.09%) ▼|XOM177.70-0.17 (-0.09%) ▼|AAPL344.66+5.16 (+1.52%) ▲|ABBV283.42-5.66 (-1.96%) ▼|ABT98.57-3.89 (-3.79%) ▼|ACN237.60-1.53 (-0.64%) ▼|ADBE255.28-1.45 (-0.56%) ▼|AMAT409.14+4.16 (+1.03%) ▲|AMD553.81+19.07 (+3.57%) ▲|AMGN437.33-1.61 (-0.37%) ▼|AMT178.95-4.61 (-2.51%) ▼|AMZN263.93+1.30 (+0.50%) ▲|AVGO338.58+4.21 (+1.26%) ▲|AXP323.66+5.32 (+1.67%) ▲|BA192.56+2.09 (+1.10%) ▲|BAC50.94+0.30 (+0.59%) ▲|BKNG158.82-5.10 (-3.11%) ▼|BLK1,142.09+13.41 (+1.19%) ▲|BMY60.82-0.87 (-1.40%) ▼|BNY146.54+2.29 (+1.59%) ▲|BRK-B542.08+2.26 (+0.42%) ▲|C123.61+1.10 (+0.90%) ▲|CAT741.55+16.31 (+2.25%) ▲|CL93.71-0.83 (-0.88%) ▼|CMCSA21.89-0.47 (-2.10%) ▼|COF208.30+6.74 (+3.34%) ▲|COP145.86-0.09 (-0.06%) ▼|COST996.30+1.69 (+0.17%) ▲|CRM242.29-0.14 (-0.06%) ▼|CSCO107.43+0.72 (+0.67%) ▲|CVS94.31-0.44 (-0.46%) ▼|CVX226.55+0.84 (+0.37%) ▲|DE632.65+0.45 (+0.07%) ▲|DHR230.57+6.33 (+2.82%) ▲|DIS111.38-0.29 (-0.26%) ▼|DUK121.06-0.28 (-0.23%) ▼|EMR164.95+4.49 (+2.80%) ▲|FDX299.55+0.79 (+0.26%) ▲|GD345.72+1.28 (+0.37%) ▲|GE298.48-1.39 (-0.46%) ▼|GEV928.88+38.55 (+4.33%) ▲|GILD153.46-3.05 (-1.95%) ▼|GM76.15-0.94 (-1.22%) ▼|GOOG330.45-5.95 (-1.77%) ▼|GOOGL334.59-5.69 (-1.67%) ▼|GS903.89+19.08 (+2.16%) ▲|HD314.43-0.68 (-0.22%) ▼|HON215.44+2.12 (+0.99%) ▲|IBM245.41+3.49 (+1.44%) ▲|INTC92.64+0.95 (+1.03%) ▲|INTU334.16-1.13 (-0.34%) ▼|ISRG429.84-8.16 (-1.86%) ▼|JNJ255.99-3.37 (-1.30%) ▼|JPM334.50-0.76 (-0.23%) ▼|KO92.67-0.82 (-0.88%) ▼|LIN502.06+0.17 (+0.03%) ▲|LLY1,270.37-13.29 (-1.04%) ▼|LMT548.75+0.04 (+0.01%) ▲|LOW196.54-0.75 (-0.38%) ▼|LRCX261.42-2.03 (-0.77%) ▼|MA623.34+2.92 (+0.47%) ▲|MCD245.86-0.66 (-0.27%) ▼|MDLZ62.47-1.53 (-2.38%) ▼|MDT93.52-1.11 (-1.17%) ▼|META707.79+13.54 (+1.95%) ▲|MMM174.01+2.64 (+1.54%) ▲|MO73.86-0.78 (-1.05%) ▼|MRK148.63+0.33 (+0.22%) ▲|MS184.97+4.57 (+2.53%) ▲|MSFT532.64+0.77 (+0.14%) ▲|MU917.85+21.78 (+2.43%) ▲|NEE78.69-0.18 (-0.22%) ▼|NFLX65.71-2.98 (-4.34%) ▼|NKE37.80-0.09 (-0.22%) ▼|NOW152.96+3.42 (+2.28%) ▲|NVDA221.37+4.90 (+2.26%) ▲|ORCL129.92-1.22 (-0.93%) ▼|PEP134.62+0.60 (+0.44%) ▲|PFE29.72-0.40 (-1.31%) ▼|PG157.73-1.59 (-1.00%) ▼|PLTR199.52+6.92 (+3.59%) ▲|PM196.84-3.07 (-1.53%) ▼|QCOM177.67+1.96 (+1.12%) ▲|RTX189.66-3.68 (-1.90%) ▼|SBUX98.74-0.64 (-0.64%) ▼|SCHW91.69+0.80 (+0.88%) ▲|SO90.53-0.18 (-0.20%) ▼|SPG206.14-0.85 (-0.41%) ▼|T21.96-1.46 (-6.23%) ▼|TMO694.24+6.87 (+1.00%) ▲|TMUS153.10-4.65 (-2.95%) ▼|TSLA386.45+12.74 (+3.41%) ▲|TXN288.23+10.45 (+3.76%) ▲|UBER68.23-0.72 (-1.04%) ▼|UNH417.32-1.94 (-0.46%) ▼|UNP289.18+1.57 (+0.55%) ▲|UPS100.18+1.66 (+1.68%) ▲|USB59.35+0.26 (+0.44%) ▲|V408.62+2.05 (+0.50%) ▲|VZ43.48-1.07 (-2.39%) ▼|WFC82.31+0.11 (+0.13%) ▲|WMT117.74-0.11 (-0.09%) ▼|XOM177.70-0.17 (-0.09%) ▼|
17.3 C
New York
Wednesday, October 21, 2026

Tag: clinical trial

newsFORsourcecompanycontentinformation1releasesmarket

Bispecifics/BiTE Market Anticipates Impressive Growth Trajectory During the Forecast Period (2025-2034) Across 7MM Due to Their Expansion Beyond Oncology | DelveInsight

The bispecific antibody and BiTE market is witnessing robust growth driven by advances in immuno-oncology and rising demand for targeted cancer therapies. Key factors...

New ExoPTEN Preclinical Study Indicates Significant Improvement in Walking Quality in Spinal Cord Injury Model

Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner 
Medium and high doses improved movement quality in up to 100% of the animals in a dose-dependent manner

Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio

Oversubscribed round was led by Future Ventures, and included NFX, BOLD Capital Partners, Kendall Capital Partners, Amplify Partners, Base4 Capital and others Dr. Emilio Emini, former SVP of...

Longeveron® Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy...

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jade Biosciences to Participate in Two Upcoming Investor Conferences

INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action...

SAN DIEGO, July 08, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, both dates inclusive (the “Class Period”), have until Monday, August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934.

Comphya Closes Oversubscribed CHF 7.5 Million Series A Round to Advance U.S. and Australian Clinical Programs Following Strong Pilot Data

- IDE approval obtained; U.S. pilot study clinical site launched at Johns Hopkins
- Series B round in planning to support pivotal U.S. trial
- New CEO appointment signals next phase of growth and expansion

Veeda Lifesciences announces partnership with Mango Sciences to bring AI innovation in clinical trials services

AHMEDABAD, India, July 8, 2025 /PRNewswire/ -- Veeda Lifesciences, a global contract research organization (CRO), has announced an investment in Mango Sciences, a Boston-based...

Novartis receives approval for first malaria medicine for newborn babies and young infants

Basel, July 8, 2025 – Novartis today announced Coartem® (artemether-lumefantrine) Baby has been approved by Swissmedic as the first malaria medicine for newborns and young infants. The new treatment, also known as Riamet® Baby in some countries, was developed in collaboration with Medicines for Malaria Venture (MMV) to treat the potentially deadly mosquito-borne disease.

Celltrion USA announces U.S. launch of denosumab biosimilars, STOBOCLO® and OSENVELT® (denosumab-bmwo)

STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and XGEVA® (denosumab) respectively,STOBOCLO and OSENVELT, among the first...

SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V

SINGAPORE, July 8, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases...

SCG Cell Therapy Announces Clearance of Investigational New Drug Application by the China NMPA for SCG101V

SINGAPORE, July 7, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases...

Johnson & Johnson Launches VARIPULSE™ Platform across Asia-Pacific, Advancing Atrial Fibrillation Treatment

The VARIPULSE™ Platform is the first Pulsed Field Ablation (PFA) system fully integrated with the CARTO™ 3 electroanatomical mapping system, designed to drive efficiency,...

Belay Diagnostics Announces the Validation of Vantage™ Assay for Evaluation of MGMT Promoter Methylation in Cerebrospinal Fluid

Validation Data on 60 Patients published in Cancer Genetics CHICAGO, July 7, 2025 /PRNewswire/ -- Belay Diagnostics, a CLIA/CAP accredited laboratory focused on the development...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers